

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER: 020884

PRINTED LABELING

AGGRENOX™
(aspirin/extended-release dipyridamole) capsules


DESCRIPTION

AGGRENOX™ is a combination antiplatelet agent intended for oral administration. Each hard gelatin capsule contains 200 mg dipyridamole in an extended-release form and 25 mg aspirin, as an immediate-release sugar-coated tablet. In addition, each capsule contains the following inactive ingredients: acacia, aluminum stearate, colloidal silicon dioxide, corn starch, dimethicone, hydroxypropyl methylcellulose, hydroxypropyl methylcellulose phthalate, lactose monohydrate, methacrylic acid copolymer, microcrystalline cellulose, povidone, stearic acid, sucrose, talc, tartaric acid, titanium dioxide and triacetin.

Each capsule shell contains gelatin, red iron oxide and yellow iron oxide, titanium dioxide and water.

Dipyridamole


Dipyridamole is an antiplatelet agent chemically described as 2,6-bis(diethanolamino)-4,8-dipiperidino-pyrimido(5,4-d) pyrimidine (= dipyridamole). It has the following structural formula:



Dipyridamole is an odorless yellow crystalline substance, having a bitter taste. It is soluble in dilute acids, methanol and chloroform, and is practically insoluble in water.

Aspirin

The antiplatelet agent aspirin (acetylsalicylic acid) is chemically known as benzoic acid, 2-(acetyloxy)-, and has the following structural formula:



Aspirin is an odorless white needle-like crystalline or powdery substance. When exposed to moisture, aspirin hydrolyzes into salicylic and acetic acids, and gives off a vinegary odor. It is highly lipid soluble and slightly soluble in water.

CLINICAL PHARMACOLOGY

Mechanism of Action

The antithrombotic action of AGGRENOX™ is the result of the additive antiplatelet effects of dipyridamole and aspirin.

Dipyridamole

Dipyridamole inhibits the uptake of adenosine into platelets, endothelial cells and erythrocytes *in vitro* and *in vivo*; the inhibition occurs in a dose-dependent manner at therapeutic concentrations (0.5–1.9 µg/mL). This inhibition results in an increase in local concentrations of adenosine which acts on the platelet A₂-receptor thereby stimulating platelet adenylate cyclase and increasing platelet cyclic-3',5'-adenosine monophosphate (cAMP) levels. Via this mechanism, platelet aggregation is inhibited in response to various stimuli such as platelet activating factor (PAF), collagen and adenosine diphosphate (ADP).

Dipyridamole inhibits phosphodiesterase (PDE) in various tissues. While the inhibition of cAMP-PDE is weak, therapeutic levels of dipyridamole inhibit cyclic-3',5'-guanosine monophosphate-PDE (cGMP-PDE), thereby augmenting the increase in cGMP produced by EDRF (endothelium-derived relaxing factor, now identified as nitric oxide).

Aspirin

Aspirin inhibits platelet aggregation by irreversible inhibition of platelet cyclo-oxygenase and thus inhibits the generation of thromboxane A₂, a powerful inducer of platelet aggregation and vasoconstriction.

Pharmacokinetics

There are no significant interactions between aspirin and dipyridamole. The kinetics of the components are unchanged by their coadministration as AGGRENOX™.

Dipyridamole

Absorption: Peak plasma levels of dipyridamole are achieved 2 hours (range 1–6 hours) after administration of a daily dose of 400 mg AGGRENOX™ (given as 200 mg b.i.d.). The peak plasma concentration at steady-state is 1.98 µg/mL (1.01–3.99 µg/mL) and the steady state trough concentration is 0.53 µg/mL (0.18–1.01 µg/mL).

Effect of Food: No food effect study has been conducted with the AGGRENOX™ formulation.

Distribution: Dipyridamole is highly lipophilic ($\log P=3.71$, $pH=7$); however, it has been shown that the drug does not cross the blood-brain barrier to any significant extent in animals. The steady-state volume of distribution of dipyridamole is about 92 L. Approximately 99% of dipyridamole is bound to plasma proteins, predominantly to alpha 1-acid glycoprotein and albumin.

Metabolism and Elimination: Dipyridamole is metabolized in the liver, primarily by conjugation with glucuronic acid, of which monoglucuronide which has low pharmacodynamic activity is the primary metabolite. In plasma, about 80% of the total amount is present as parent compound and 20% as monoglucuronide. Most of the glucuronide metabolite (about 95%) is excreted via bile into the feces, with some evidence of enterohepatic circulation. Renal excretion of parent compound is negligible and urinary excretion of the glucuronide metabolite is low (about 5%). With intravenous (i.v.) treatment of dipyridamole, a triphasic profile is obtained: a rapid alpha phase, with a half-life of about 3.4 minutes, a beta phase, with a half-life of about 39 minutes, (which, together with the alpha phase accounts for about 70% of the total area under the curve, AUC) and a prolonged elimination phase λ_z with a half-life of about 15.5 hours. Due to the extended absorption phase of the dipyridamole component, only the terminal phase is apparent from oral treatment with AGGRENOX™ which, in trial 9.123 was 13.6 hours.

Special Populations: Geriatric Patients: In ESPS2 (See CLINICAL PHARMACOLOGY, Clinical Trials), plasma concentrations (determined as AUC) of dipyridamole in healthy elderly subjects (>65 years) were about 40% higher than in subjects younger than 55 years receiving treatment with AGGRENOX™.

Hepatic Dysfunction: No study has been conducted with the AGGRENOX™ formulation in patients with hepatic dysfunction.

In a study conducted with an intravenous formulation of dipyridamole, patients with mild to severe hepatic insufficiency showed no change in plasma concentrations of dipyridamole but showed an increase in the pharmacologically inactive monoglucuronide metabolite. Dipyridamole can be dosed without restriction as long as there is no evidence of hepatic failure.

Renal Dysfunction: No study has been conducted with the AGGRENOX™ formulation in patients with renal dysfunction.

In ESPS2 patients (See CLINICAL PHARMACOLOGY, Clinical Trials), with creatinine clearances ranging from about 15 mL/min to >100 mL/min, no changes were observed in the pharmacokinetics of dipyridamole or its glucuronide metabolite if data were corrected for differences in age.

Aspirin

Absorption: Peak plasma levels of aspirin are achieved 0.63 hours (0.5–1 hours) after administration of a 50 mg aspirin daily dose from AGGRENOX™ (given as 25 mg b.i.d.). The peak plasma concentration at steady-state is 319 ng/mL (175–463 ng/mL). Aspirin undergoes moderate hydrolysis to salicylic acid in the liver and the gastrointestinal wall, with 50%–75% of an administered dose reaching the systemic circulation as intact aspirin.

Distribution: Aspirin is poorly bound to plasma proteins and its apparent volume of distribution is low (10 L). Its metabolite, salicylic acid, is highly bound to plasma proteins, but its binding is concentration-dependent (nonlinear). At low concentrations (<100 µg/mL), approximately 90% of salicylic acid is bound to albumin. Salicylic acid is widely distributed to all tissues and fluids in the body, including the central nervous system, breast milk, and fetal tissues. Early signs of salicylate overdose (salicylism), including tinnitus (ringing in the ears), occur at plasma concentrations approximating 200 µg/mL (See **ADVERSE REACTIONS; OVERDOSAGE**).

Metabolism and Elimination: Aspirin is rapidly hydrolyzed in plasma to salicylic acid, with a half-life of 20 minutes. Plasma levels of aspirin are essentially undetectable 2–2.5 hours after dosing and peak salicylic acid concentrations occur 1 hour (range: 0.5–2 hours) after administration of aspirin. Salicylic acid is primarily conjugated in the liver to form salicyluric acid, a phenolic glucuronide, an acyl glucuronide, and a number of minor metabolites. Salicylate metabolism is saturable and total body clearance decreases at higher serum concentrations due to the limited ability of the liver to form both salicyluric acid and phenolic glucuronide. Following toxic doses (10–20 g), the plasma half-life may be increased to over 20 hours.

The elimination of acetylsalicylic acid follows first-order kinetics with AGGRENOX™ and has a half-life of 0.33 hours. The half-life of salicylic acid is 1.71 hours. Both values correspond well with data from the literature at lower doses which state a resultant half-life of approximately 2–3 hours. At higher doses, the elimination of salicylic acid follows zero-order kinetics (i.e., the rate of elimination is constant in relation to plasma concentration), with an apparent half-life of 6 hours or higher. Renal excretion of unchanged drug depends upon urinary pH. As urinary pH rises above 6.5, the renal clearance of free salicylate increases from <5% to >80%. Alkalinization of the urine is a key concept in the management of salicylate overdose (See **OVERDOSAGE**). Following therapeutic doses, about 10% is excreted as salicylic acid and 75% as salicyluric acid, as the phenolic and acyl glucuronides, in urine.

Special Populations:

Hepatic Dysfunction: Aspirin is to be avoided in patients with severe hepatic insufficiency.

Renal Dysfunction: Aspirin is to be avoided in patients with severe renal failure (glomerular

filtration rate less than 10 mL/min).

Clinical Trials

AGGRENOX™ was studied in a double-blind, placebo-controlled, 24-month study (European Stroke Prevention Study 2, ESPS2) in which 6602 patients had an ischemic stroke (76%) or transient ischemic attack (TIA, 24%) within three months prior to entry. Patients were randomized to one of four treatment groups: AGGRENOX™ (aspirin/extended-release dipyridamole) 25 mg/200 mg; extended-release dipyridamole (ER-DP) 200 mg alone; aspirin (ASA) 25 mg alone; or placebo. Patients received one capsule twice daily (morning and evening). Efficacy assessments included analyses of stroke (fatal or nonfatal) and death (from all causes) as confirmed by a blinded morbidity and mortality assessment group.


Stroke Endpoint: AGGRENOX™ reduced the risk of stroke by 22.1% compared to aspirin 50 mg/day alone ($p = 0.008$) and reduced the risk of stroke by 24.4% compared to extended-release dipyridamole 400 mg/day alone ($p = 0.002$) (Table 1). AGGRENOX™ reduced the risk of stroke by 36.8% compared to placebo ($p < 0.001$).

Table 1: Summary of First Stroke (Fatal or Nonfatal)
ESPS2: Intent-to-Treat Population

	Total Number of Patients n	Number of Patients With Stroke Within 2 Years n (%)	Kaplan-Meier Estimate of Survival at 2 Years (95% C.I.)	Gehan- Wilcoxon Test P-value	Risk Reduction at 2 Years	Odds Ratio (95% C.I.)
Individual Treatment Group						
AGGRENOX™	1650	157 (9.5%)	89.9% (88.4%, 91.4%)	-	-	-
ER-DP	1654	211 (12.8%)	86.7% (85.0%, 88.4%)	-	-	-
ASA	1649	206 (12.5%)	87.1% (85.4%, 88.7%)	-	-	-
Placebo	1649	250 (15.2%)	84.1% (82.2%, 85.9%)	-	-	-
Pairwise Treatment Group Comparisons						
AGGRENOX™ vs. ER-DP	-	-	-	0.002**	24.4%	0.72 (0.58, 0.90)
AGGRENOX™ vs. ASA	-	-	-	0.008**	22.1%	0.74 (0.59, 0.92)
AGGRENOX™ vs. Placebo	-	-	-	<0.001**	36.8%	0.59 (0.48, 0.73)
ER-DP vs. Placebo	-	-	-	0.036*	16.5%	0.82 (0.67, 1.00)
ASA vs. Placebo	-	-	-	0.009**	18.9%	0.80 (0.66, 0.97)

* $0.010 < p\text{-value} \leq 0.050$; ** $p\text{-value} \leq 0.010$.

Note: ER-DP = extended-release dipyridamole 200 mg; ASA = aspirin 25 mg. The dosage regimen for all treatment groups is b.i.d.



Note: ER-DP – extended-release dipyridamole 200 mg; ASA – aspirin 25 mg.

Note: The dosage regimen for all treatment groups is b.i.d.

Combined Stroke or Death Endpoint: In ESPS2, AGGRENOX™ reduced the risk of stroke or death by 12.1% compared to aspirin alone and by 10.3% compared to extended-release dipyridamole alone. These results were not statistically significant.

AGGRENOX™ reduced the risk of stroke or death by 24.2% compared to placebo.

Death Endpoint: The incidence rate of all cause mortality was 11.3% for Aggrenox™, 11.0% for aspirin alone, 11.4% for extended-release dipyridamole alone and 12.3% for placebo alone. The differences between the Aggrenox™, aspirin alone and extended-release dipyridamole alone treatment groups were not statistically significant. These incidence rates for Aggrenox™ and aspirin alone are consistent with previous aspirin studies in stroke and TIA patients.

INDICATIONS AND USAGE

AGGRENOX™ is indicated to reduce the risk of stroke in patients who have had transient ischemia of the brain or completed ischemic stroke due to thrombosis.

CONTRAINDICATIONS

AGGRENOX™ is contraindicated in patients with hypersensitivity to dipyridamole, aspirin or any of the other product components.

Allergy: Aspirin is contraindicated in patients with known allergy to nonsteroidal anti-inflammatory drug products and in patients with the syndrome of asthma, rhinitis, and nasal polyps. Aspirin may cause severe urticaria, angioedema or bronchospasm (asthma).

Reye's Syndrome: Aspirin should not be used in children or teenagers for viral infections, with or without fever, because of the risk of Reye's syndrome with concomitant use of aspirin in certain viral illnesses.

WARNINGS

Alcohol Warning: Patients who consume three or more alcoholic drinks every day should be counseled about the bleeding risks involved with chronic, heavy alcohol use while taking aspirin.

Coagulation Abnormalities: Even low doses of aspirin can inhibit platelet function leading to an increase in bleeding time. This can adversely affect patients with inherited or acquired (liver disease or vitamin K deficiency) bleeding disorders.

Gastrointestinal (GI) Side Effects: GI side effects include stomach pain, heartburn, nausea, vomiting, and gross GI bleeding. Although minor upper GI symptoms, such as dyspepsia, are common and can occur anytime during therapy, physicians should remain alert for signs of ulceration and bleeding, even in the absence of previous GI symptoms. Physicians should inform patients about the signs and symptoms of GI side effects and what steps to take if they occur.

Peptic Ulcer Disease: Patients with a history of active peptic ulcer disease should avoid using aspirin, which can cause gastric mucosal irritation and bleeding.

PRECAUTIONS

General

AGGRENOX™ is not interchangeable with the individual components of aspirin and Persantine® Tablets.

Coronary Artery Disease: Dipyridamole has a vasodilatory effect and should be used with caution in patients with severe coronary artery disease (e.g., unstable angina or recently sustained

myocardial infarction). Chest pain may be aggravated in patients with underlying coronary artery disease who are receiving dipyridamole.

For stroke or TIA patients for whom aspirin is indicated to prevent recurrent myocardial infarction (MI) or angina pectoris, the aspirin in this product may not provide adequate treatment for the cardiac indications.

Hepatic Insufficiency: Elevations of hepatic enzymes and hepatic failure have been reported in association with dipyridamole administration.

Hypotension: Dipyridamole should be used with caution in patients with hypotension since it can produce peripheral vasodilation.

Renal Failure: Avoid aspirin in patients with severe renal failure (glomerular filtration rate less than 10 mL/minute).

Risk of Bleeding: In ESPS2 the incidence of gastrointestinal bleeding was 68 patients (4.1%) in the AGGRENOX™ group, 36 patients (2.2%) in the dipyridamole group, 52 patients (3.2%) in the aspirin group, and 34 patients (2.1%) in the placebo groups.

The incidence of intracranial hemorrhage was 9 patients (0.6%) in the AGGRENOX™ group, 6 patients (0.5%) in the dipyridamole group, 6 patients (0.4%) in the aspirin group and 7 patients (0.4%) in the placebo groups.

Laboratory Tests

Aspirin has been associated with elevated hepatic enzymes, blood urea nitrogen and serum creatinine, hyperkalemia, proteinuria and prolonged bleeding time.

Dipyridamole has been associated with elevated hepatic enzymes.

Drug Interactions

No pharmacokinetic drug-drug interaction studies were conducted with the AGGRENOX™ formulation. The following information was obtained from the literature.

Adenosine: Dipyridamole has been reported to increase the plasma levels and cardiovascular effects of adenosine. Adjustment of adenosine dosage may be necessary.

Angiotensin Converting Enzyme (ACE) Inhibitors: Due to the indirect effect of aspirin on the renin-angiotensin conversion pathway, the hyponatremic and hypotensive effects of ACE inhibitors may be diminished by concomitant administration of aspirin.

Acetazolamide: Concurrent use of aspirin and acetazolamide can lead to high serum concentrations of acetazolamide (and toxicity) due to competition at the renal tubule for secretion.

Anticoagulant Therapy (heparin and warfarin): Patients on anticoagulation therapy are at increased risk for bleeding because of drug-drug interactions and effects on platelets. Aspirin can displace warfarin from protein binding sites, leading to prolongation of both the prothrombin time and the bleeding time. Aspirin can increase the anticoagulant activity of heparin, increasing bleeding risk.

Anticonvulsants: Salicylic acid can displace protein-bound phenytoin and valproic acid, leading to a decrease in the total concentration of phenytoin and an increase in serum valproic acid levels.

Beta Blockers: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow and salt and fluid retention.

Cholinesterase Inhibitors: Dipyridamole may counteract the anticholinesterase effect of cholinesterase inhibitors, thereby potentially aggravating myasthenia gravis.

Diuretics: The effectiveness of diuretics in patients with underlying renal or cardiovascular disease may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow and salt and fluid retention.

Methotrexate: Salicylate can inhibit renal clearance of methotrexate, leading to bone marrow toxicity, especially in the elderly or renal impaired.

Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): The concurrent use of aspirin with other NSAIDs may increase bleeding or lead to decreased renal function.

Oral Hypoglycemics: Moderate doses of aspirin may increase the effectiveness of oral hypoglycemic drugs, leading to hypoglycemia.

Uricosuric Agents (probenecid and sulfapyrazone): Salicylates antagonize the uricosuric action of uricosuric agents.

Carcinogenesis, Mutagenesis, Impairment of Fertility: Carcinogenesis: Dipyridamole: In a 111-week oral study in mice and in a 128-142-week oral study in rats, Persantine® (dipyridamole USP) produced no significant carcinogenic effects at doses of 8, 25 and 75 mg/kg. For a 50-kg person of average height (1.46 m² body surface area), the dose of dipyridamole at 75 mg/kg/day (225 mg/m²/day in mice or 450 mg/m²/day in rats) represents 0.76 or 1.5 times the recommended human dose (8 mg/kg/day or 296 mg/m²/day) on a body surface area basis.

Mutagenicity: Combination of Dipyridamole and Aspirin: Mutagenicity testing with combination of dipyridamole and aspirin in a ratio of 1:5 revealed no mutagenic potential in the Ames test, *in vivo* chromosome aberration tests in mice and hamsters, oral micronucleus tests in mice and hamsters and dominant lethal test in mice. Aspirin induced chromosome aberrations in cultured human fibroblasts.

Fertility: Dipyridamole: Reproduction studies with Persantine® revealed no evidence of impaired fertility in rats at oral dosages of up to 500 mg/kg/day or 3000 mg/m²/day (~10 times the recommended human dose on a body surface area basis). A significant reduction in number of corpora lutea with consequent reduction in implantations and live fetuses was, however, observed at dose of Persantine® of 1250 mg/kg/day or 7500 mg/m²/day in rats (~25 times the recommended human dose on a body surface area basis).

Aspirin: Aspirin inhibits ovulation in rats.

Combination of Dipyridamole and Aspirin: Combination of dipyridamole and aspirin was not tested for effect on fertility and reproductive performance.

Dipyridamole: Pregnancy Category B: Reproduction studies with dipyridamole have been performed in mice at doses up to 125 mg/kg (375 mg/m², ~1.3 times the recommended human dose), in rats at doses up to 1000 mg/kg (6000 mg/m², 20 times the recommended human dose) and in rabbits at doses up to 40 mg/kg (480 mg/m², ~1.6 times the recommended human dose) and have revealed no evidence of harm to the fetus.

Aspirin: Pregnancy Category D: Aspirin may produce adverse maternal effects: anemia, ante- or postpartum hemorrhage, prolonged gestation and labor. Maternal aspirin use during later stages of pregnancy may cause adverse fetal effects: low birth weight, increased incidence of intracranial hemorrhage in premature infants, stillbirths, neonatal death. Aspirin should be avoided 1 week prior to and during labor and delivery because it can result in excessive blood loss at delivery.

Reproduction studies have been performed with combination of dipyridamole and aspirin in a ratio of 1:4.4 in rats and rabbits and have revealed no teratogenic evidence at doses of up to 405 mg/kg/day in rats and 135 mg/kg/day in rabbits. However, treatment with combination of dipyridamole and aspirin at 405 mg/kg/day induced abortion in rats. The doses of dipyridamole at 75 mg/kg/day represent 1.5 times the recommended human dose on a body surface area basis. In these studies, aspirin itself was teratogenic at doses of 330 mg/kg/day (1980 mg/m²/day) in rats (spina bifida, exencephaly, microphthalmia, and coelosomia) and 110 mg/kg/day (1320 mg/m²/day) in rabbits (congested fetuses, agenesis of skull and upper jaw, generalized edema with malformation of the head, and diaphanous skin). The doses of aspirin at 330 mg/kg/day in rats and at 110 mg/kg/day in rabbits were ~54 and 36 times the recommended human

dose, respectively, on a body surface area basis.

There were no adequate and well-controlled studies in pregnant women. AGGRENOX™ should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Due to the aspirin component, AGGRENOX™ should be avoided in the third trimester of pregnancy.

Nursing Mothers

Dipyridamole (n=1) and aspirin are excreted in human breast milk in low concentrations. Therefore, caution should be exercised when AGGRENOX™ is administered to a nursing woman.

Pediatric Use

Safety and effectiveness of AGGRENOX™ in pediatric patients have not been studied. Due to the aspirin component, use of this product in the pediatric population is not recommended (See CONTRAINDICATIONS).

ADVERSE REACTIONS

A 24-month, multicenter, double-blind, randomized study (ESPS2) was conducted to compare the efficacy and safety of AGGRENOX™ with placebo, extended-release dipyridamole alone and aspirin alone. The study was conducted in a total of 6602 male and female patients who had experienced a previous ischemic stroke or transient ischemia of the brain within three months prior to randomization.

Table 2 presents the incidence of adverse events that occurred in 1% or more of patients treated with AGGRENOX™ where the incidence was also greater than in those patients treated with placebo. There is no clear benefit of the dipyridamole/aspirin combination over aspirin with respect to safety.

Table 2: Incidence of Adverse Events in ESPS2*

Body System/Preferred Term	Individual Treatment Group			
	AGGRENOX™	ER-DP Alone	ASA Alone	Placebo
Total Number of Patients	1650	1654	1649	1649
Total Number (%) of Patients With at Least One On-Treatment Adverse Event	1319 (79.9%)	1305 (78.9%)	1323 (80.2%)	1304 (79.1%)
Central & Peripheral Nervous System Disorders				
Headache	647 (39.2%)	634 (38.3%)	558 (33.8%)	543 (32.9%)
Convulsions	28 (1.7%)	15 (0.9%)	28 (1.7%)	26 (1.6%)
Gastro-Intestinal System Disorders				
Dyspepsia	303 (18.4%)	288 (17.4%)	299 (18.1%)	275 (16.7%)
Abdominal Pain	289 (17.5%)	255 (15.4%)	262 (15.9%)	239 (14.5%)
Nausea	264 (16.0%)	254 (15.4%)	210 (12.7%)	232 (14.1%)
Diarrhea	210 (12.7%)	257 (15.5%)	112 (6.8%)	161 (9.8%)
Vomiting	138 (8.4%)	129 (7.8%)	101 (6.1%)	118 (7.2%)
Hemorrhage Rectum	26 (1.6%)	22 (1.3%)	16 (1.0%)	13 (0.8%)
Melena	31 (1.9%)	10 (0.6%)	20 (1.2%)	13 (0.8%)
Hemorrhoids	16 (1.0%)	13 (0.8%)	10 (0.6%)	10 (0.6%)
GI Hemorrhage	20 (1.2%)	5 (0.3%)	15 (0.9%)	7 (0.4%)

* Reported by $\geq 1\%$ of patients during AGGRENOX™ treatment where the incidence was greater than in those treated with placebo.

Note: ER-DP = extended-release dipyridamole 200 mg; ASA = aspirin 25 mg.

Note: The dosage regimen for all treatment groups is b.i.d.

Note: NOS = not otherwise specified.

Table 2: (continued) Incidence of Adverse Events in ESPS2*

Body System/Preferred Term	Individual Treatment Group			
	AGGRENOX ™	ER-DP Alone	ASA Alone	Placebo
Body as a Whole – General Disorders				
Pain	105 (6.4%)	88 (5.3%)	103 (6.2%)	99 (6.0%)
Fatigue	95 (5.8%)	93 (5.6%)	97 (5.9%)	90 (5.5%)
Back Pain	76 (4.6%)	77 (4.7%)	74 (4.5%)	65 (3.9%)
Accidental Injury	42 (2.5%)	24 (1.5%)	51 (3.1%)	37 (2.2%)
Malaise	27 (1.6%)	23 (1.4%)	26 (1.6%)	22 (1.3%)
Asthenia	29 (1.8%)	19 (1.1%)	17 (1.0%)	18 (1.1%)
Syncope	17 (1.0%)	13 (0.8%)	16 (1.0%)	8 (0.5%)
Psychiatric Disorders				
Amnesia	39 (2.4%)	40 (2.4%)	57 (3.5%)	34 (2.1%)
Confusion	18 (1.1%)	9 (0.5%)	22 (1.3%)	15 (0.9%)
Anorexia	19 (1.2%)	17 (1.0%)	10 (0.6%)	15 (0.9%)
Somnolence	20 (1.2%)	13 (0.8%)	18 (1.1%)	9 (0.5%)
Musculoskeletal System Disorders				
Arthralgia	91 (5.5%)	75 (4.5%)	91 (5.5%)	76 (4.6%)
Arthritis	34 (2.1%)	25 (1.5%)	17 (1.0%)	19 (1.2%)
Arthrosis	18 (1.1%)	22 (1.3%)	13 (0.8%)	14 (0.8%)
Myalgia	20 (1.2%)	16 (1.0%)	11 (0.7%)	11 (0.7%)
Respiratory System Disorders				
Coughing	25 (1.5%)	18 (1.1%)	32 (1.9%)	21 (1.3%)
Upper Respiratory Tract Infection	16 (1.0%)	9 (0.5%)	16 (1.0%)	14 (0.8%)
Cardiovascular Disorders, General				
Cardiac Failure	26 (1.6%)	17 (1.0%)	30 (1.8%)	25 (1.5%)
Platelet, Bleeding & Clotting Disorders				
Hemorrhage NOS	52 (3.2%)	24 (1.5%)	46 (2.8%)	24 (1.5%)
Epistaxis	39 (2.4%)	16 (1.0%)	45 (2.7%)	25 (1.5%)
Purpura	23 (1.4%)	8 (0.5%)	9 (0.5%)	7 (0.4%)
Neoplasm				
Neoplasm NOS	28 (1.7%)	16 (1.0%)	23 (1.4%)	20 (1.2%)
Red Blood Cell Disorders				
Anemia	27 (1.6%)	16 (1.0%)	19 (1.2%)	9 (0.5%)

* Reported by $\geq 1\%$ of patients during AGGRENOX™ treatment where the incidence was greater than in those treated with placebo.

Note: ER-DP = extended-release dipyridamole 200 mg; ASA = aspirin 25 mg.

Note: The dosage regimen for all treatment groups is b.i.d.

Note: NOS = not otherwise specified.

Discontinuation due to adverse events in ESPS2 was 25% for AGGRENOX™, 25% for extended-release dipyridamole, 19% for aspirin, and 21% for placebo (refer to Table 3).

Table 3: Incidence of Adverse Events that Led to the Discontinuation of Treatment: Adverse Events with an Incidence of $\geq 1\%$ in the AGGRENOX™ group

	Treatment Groups			
	AGGRENOX™	ER-DP	ASA	Placebo
Total Number of Patients	1650	1654	1649	1649
Patients with at least one Adverse Event that led to treatment discontinuation	417 (25%)	419 (25%)	318 (19%)	352 (21%)
Headache	165 (10%)	166 (10%)	57 (3%)	69 (4%)
Dizziness	85 (5%)	97 (6%)	69 (4%)	68 (4%)
Nausea	91 (6%)	95 (6%)	51 (3%)	53 (3%)
Abdominal Pain	74 (4%)	64 (4%)	56 (3%)	52 (3%)
Dyspepsia	59 (4%)	61 (4%)	49 (3%)	46 (3%)
Vomiting	53 (3%)	52 (3%)	28 (2%)	24 (1%)
Diarrhea	35 (2%)	41 (2%)	9 (<1%)	16 (<1%)
Stroke	39 (2%)	48 (3%)	57 (3%)	73 (4%)
Transient Ischemic Attack	35 (2%)	40 (2%)	26 (2%)	48 (3%)
Angina Pectoris	23 (1%)	20 (1%)	16 (<1%)	26 (2%)

Note: ER-DP = extended-release dipyridamole 200 mg; ASA = aspirin 25 mg. The dosage regimen for all treatment groups is b.i.d.

Other adverse events:

Adverse reactions that occurred in less than 1% of patients treated with AGGRENOX™ in the ESPS2 study and that were medically judged to be possibly related to either dipyridamole or aspirin are listed below (See WARNINGS). *Body as a Whole:* Allergic reaction, fever.

Cardiovascular: Hypotension. *Central Nervous System:* Coma, dizziness, paresthesia, cerebral hemorrhage, intracranial hemorrhage, subarachnoid hemorrhage. *Gastrointestinal:* Gastritis, ulceration and perforation. *Hearing & Vestibular Disorders:* Tinnitus, and deafness. Patients with

high frequency hearing loss may have difficulty perceiving tinnitus. In these patients, tinnitus cannot be used as a clinical indicator of salicylism. *Heart Rate and Rhythm Disorders:* Tachycardia, palpitation, arrhythmia, supraventricular tachycardia. *Liver and Biliary System Disorders:* Cholelithiasis, jaundice, hepatic function abnormal. *Metabolic & Nutritional Disorders:* Hyperglycemia, thirst. *Platelet, Bleeding and Clotting Disorders:* Hematoma, gingival bleeding. *Psychiatric Disorders:* Agitation. *Reproductive:* Uterine hemorrhage. *Respiratory:* Hyperpnea, asthma, bronchospasm, hemoptysis, pulmonary edema. *Special Senses Other Disorders:* Taste loss. *Skin and Appendages Disorders:* Pruritus, urticaria. *Urogenital:* Renal insufficiency and failure, hematuria. *Vascular (Extracardiac) Disorders:* Flushing.

The following is a list of additional adverse reactions that have been reported either in the literature or are from postmarketing spontaneous reports for either dipyridamole or aspirin. *Body as a Whole:* Hypothermia, chest pain. *Cardiovascular:* Angina pectoris. *Central Nervous System:* Cerebral edema. *Fluid and Electrolyte:* Hyperkalemia, metabolic acidosis, respiratory alkalosis, hypokalemia. *Gastrointestinal:* Pancreatitis, Reye's syndrome, hematemesis. *Hearing and Vestibular Disorders:* Hearing loss. *Hypersensitivity:* Acute anaphylaxis, laryngeal edema. *Liver and Biliary System Disorders:* Hepatitis, hepatic failure. *Musculoskeletal:* Rhabdomyolysis. *Metabolic & Nutritional Disorders:* Hypoglycemia, dehydration. *Platelet, Bleeding and Clotting Disorders:* Prolongation of the prothrombin time, disseminated intravascular coagulation, coagulopathy, thrombocytopenia. *Reproductive:* Prolonged pregnancy and labor, stillbirths, lower birth weight infants, antepartum and postpartum bleeding. *Respiratory:* Tachypnea, dyspnea. *Skin and Appendages Disorders:* Rash, alopecia, angioedema, Stevens-Johnson syndrome. *Urogenital:* Interstitial nephritis, papillary necrosis, proteinuria. *Vascular (Extracardiac Disorders):* Allergic vasculitis.

The following is a list of adverse events that have been reported either in the literature or are from postmarketing spontaneous reports for either dipyridamole or aspirin. The causal relationship of these adverse events has not been established: anorexia, aplastic anemia, pancytopenia, thrombocytosis.

Laboratory Changes

Over the course of the 24-month study (ESPS2), patients treated with AGGRENOX™ showed a decline (mean change from baseline) in hemoglobin of 0.25 g/dL, hematocrit of 0.75%, and erythrocyte count of $0.13 \times 10^6/\text{mm}^3$.

OVERDOSAGE

Because of the dose ratio of dipyridamole to aspirin, overdosage of AGGRENOX™ is likely to be dominated by signs and symptoms of dipyridamole overdose. In case of real or suspected overdose, seek medical attention or contact a Poison Control Center immediately. Careful medical management is essential.

Dipyridamole

Based upon the known hemodynamic effects of dipyridamole, symptoms such as warm feeling, flushes, sweating, restlessness, feeling of weakness and dizziness may occur. A drop in blood pressure and tachycardia might also be observed.

Symptomatic treatment is recommended, possibly including a vasopressor drug. Gastric lavage should be considered. Since dipyridamole is highly protein bound, dialysis is not likely to be of benefit.

Aspirin

Salicylate toxicity may result from acute ingestion (overdose) or chronic intoxication. The early signs of salicylic overdose (salicylism), including tinnitus (ringing in the ears), occur at plasma concentrations approaching 200 µg/mL. Plasma concentrations of aspirin above 300 µg/mL are clearly toxic. Severe toxic effects are associated with levels above 400 µg/mL. A single lethal dose of aspirin in adults is not known with certainty but death may be expected at 30 g.

Treatment consists primarily of supporting vital functions, increasing salicylate elimination, and correcting the acid-base disturbance. Gastric emptying and/or lavage are recommended as soon as possible after ingestion, even if the patient has vomited spontaneously. After lavage and/or emesis, administration of activated charcoal, as a slurry, is beneficial, if less than 3 hours have passed since ingestion. Charcoal absorption should not be employed prior to emesis and lavage.

Severity of aspirin intoxication is determined by measuring the blood salicylate level. Acid-base status should be closely followed with serial blood gas and serum pH measurements. Fluid and electrolyte balance should also be maintained.

In severe cases, hyperthermia and hypovolemia are the major immediate threats to life. Children should be sponged with tepid water. Replacement fluid should be administered intravenously and augmented with correction of acidosis. Plasma electrolytes and pH should be monitored to promote alkaline diuresis of salicylate if renal function is normal. Infusion of glucose may be required to control hypoglycemia.

Hemodialysis and peritoneal dialysis can be performed to reduce the body drug content. In patients with renal insufficiency or in cases of life-threatening intoxication, dialysis is usually required. Exchange transfusion may be indicated in infants and young children.

AGGRENOX™

A single oral dose of combination of dipyridamole and aspirin at doses of up to 6.75 g/kg in a ratio of 8:1 was non-lethal in rats. Decreased locomotor activity, prone position and piloerection were observed at doses of combination of dipyridamole and aspirin at 2.25 and 6.75 g/kg.

DOSAGE AND ADMINISTRATION

The recommended dose of AGGRENEX™ is one capsule given orally twice daily, one in the morning and one in the evening. The capsules should be swallowed whole without chewing.

AGGRENEX™ is not interchangeable with the individual components of aspirin and Persantine® Tablets.

HOW SUPPLIED

AGGRENEX™ is available as a hard gelatin capsule, with a red cap and an ivory-colored body, 24.0 mm in length, containing yellow extended-release pellets incorporating dipyridamole and a round white tablet incorporating immediate-release aspirin. The capsule body is imprinted in red with the Boehringer Ingelheim logo and with "01A".

AGGRENEX™ is supplied in bottles of 60 capsules (NDC 0597-0001-60).

Store at 25°C (77°F); excursions permitted to 15°–30°C (59°–86°F).

Protect from excessive moisture.

Manufactured by:

Boehringer Ingelheim Pharma KG

Biberach, Germany

Distributed by:

Boehringer Ingelheim Pharmaceuticals Inc.,

Ridgefield, CT 06877

R_x only

**APPEARS THIS WAY
ON ORIGINAL**